Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raloxifene, a new selective estrogen receptor modulator.

D Goldfrank1, T Haytoglu, W H Frishman

  • 1Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.

Journal of Clinical Pharmacology
|August 6, 1999
PubMed
Summary

Selective estrogen receptor modulators like raloxifene may offer cardiovascular benefits for postmenopausal women. Further human studies are needed to confirm raloxifene's anti-atherosclerotic effects and safety profile.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic insights into racing camels: inbreeding levels and positive selection linked to athletic traits.

Animal : an international journal of animal bioscience·2025
Same author

AIDS and the heart: Clinicopathologic assessment.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology·2015
Same author

ACE inhibitors and the arterial wall. Introduction.

Postgraduate medicine·2009
Same author

Pathophysiology and medical management of systemic hypertension and pre-eclampsia in pregnancy.

Minerva medica·2006
Same author

Disease genes and chromosomes: disease maps of the human genome. Chromosome 4.

Genetic testing·2004
Same author

No useful role for fine needle aspiration as a marker for familial breast cancer.

Breast (Edinburgh, Scotland)·2004

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Oncology

Background:

  • Estrogen replacement therapy (ERT) in postmenopausal women is linked to reduced atherosclerotic heart disease morbidity and mortality.
  • Potential mechanisms include favorable effects on plasma lipids and vascular endothelial function.
  • However, estrogens increase breast and uterine cancer risks.

Purpose of the Study:

  • To evaluate the cardiovascular and oncological profile of the selective estrogen receptor modulator (SERM) raloxifene.
  • To compare raloxifene's effects with those of estrogen and tamoxifen.

Main Methods:

  • Observational studies on ERT.
  • Animal studies investigating raloxifene's anti-atherosclerotic action.
  • Clinical data on raloxifene's effects on lipids, osteoporosis, and uterine carcinoma rates.

Related Experiment Videos

Main Results:

  • Raloxifene demonstrates potential benefits on plasma lipids and osteoporosis, similar to estrogen.
  • Unlike estrogen and tamoxifen, raloxifene does not appear to increase uterine carcinoma rates.
  • Animal studies suggest raloxifene may have anti-atherosclerotic properties.

Conclusions:

  • Raloxifene presents a potential alternative to ERT for postmenopausal women, offering cardiovascular and bone health benefits without increasing uterine cancer risk.
  • Long-term human studies are required to validate the anti-atherosclerotic effects of raloxifene.